Skip to main content
. 2007 Dec 19;11(Suppl 5):S6. doi: 10.1186/cc6157

Table 4.

Guidelines for interrupting drotrecogin alfa (activated) infusion for an invasive procedure

Procedurea Pre-procedure: stop DrotAA Post-procedure: reconsider DrotAAb
Minor procedure
 Arterial line insertion 2 hours before procedure Immediately afterward
 Venous femoral line insertion 2 hours before procedure Immediately afterward
 Re-intubation (tube change) 2 hours before procedure Immediately afterward
More invasive procedure
 Central venous catheter insertion via compressible site (e.g. via femoral vein) 2 hours before procedure Immediately afterward
 Central venous catheter insertion via noncompressible site (e.g. via subclavian or jugular vein) 2 hours before procedure 2 hours afterward
 Chest tube insertion or thoracic drainage 2 hours before procedure 2 hours afterward
 Gastroscopy (possible biopsy) 2 hours before procedure 2 hours afterward
 Lumbar puncture 2 hours before procedure 2 hours afterward
 Nephrostomy 2 hours before procedure 2 hours afterward
 Paracentesis 2 hours before procedure 2 hours afterward
 Percutaneous drainage 2 hours before procedure 2 hours afterward
 Sinus puncture 2 hours before procedure 2 hours afterward
 Tracheostomy 2 hours before procedure 1 hour afterward
 Wound debridement (decubitus ulcer, infected wound, packing changes in open abdomen, etc.) 2 hours before procedure 2 hours afterward
Major procedure
 Major surgical procedurec 2 hours before procedure Wait 12 hours
 Epidural catheter 2 hours before procedure; withhold drotrecogin alfa (activated) while catheter present Wait at least 12 hours after catheter removal before initiating drotrecogin alfa (activated) infusion
Other
 CPR When beginning CPR Evaluate neurologic status before resuming drotrecogin alfa (activated). If chest trauma occurred, wait 12 hours

aThese guidelines assume that the procedures listed (with the exception of initiation of cardiopulmonary resuscitation [CPR]) are non-emergency. For emergency procedures, the drotrecogin alfa (activated; DrotAA) infusion should be discontinued as soon as possible. The subsequent decision regarding whether and when to reinitiate the infusion depends on the type of procedure and the patient's clinical condition. bIf no signs and symptoms of bleeding are present and the investigator/clinician feels that there is minimal risk for bleeding complications. cA significant surgical procedure that requires the use of an operating room, anesthesia, and so on. DrotAA, drotrecogin alfa (activated). Modified with permission from Laterre and Wittebole [23].